July 25, 2024 07:29 AM EDTUpdated 10:23 AM
Pharma
Manufacturing

Sanofi eyes RSV an­ti­body for its next block­buster while Dupix­ent brings in record sales

Anna Brown

News Reporter

Sanofi’s RSV an­ti­body Bey­for­tus is still on track to reach block­buster sta­tus this year as the com­pa­ny ex­pands man­u­fac­tur­ing ca­pac­i­ty, ac­cord­ing to re­marks made Thurs­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times